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Miguel N. Burnier Jr., MD, PhD, FRCSCAbstractAlthough rare, uveal melanoma is the most common intraocular tumor in adults. Most cases arise from the choroidal layer of the
uvea, displaying a discoid, collar-button, or mushroom shaped growth. Histopathologically, neoplasms are classified by the dom-
inant cell type: spindle, epithelioid or mixed spindle cell type. The most important prognostic factors are cell type, nucleolar size,
largest tumor dimension, and mitotic figures. Patient prognosis is poor when metastases occur in the liver, one of the main reasons
that despite advances in the diagnosis and treatment of uveal melanoma, the mortality rate has not change significantly since
1973.
Keywords: Uveal melanoma, Cancer, Metastasis, Choroidal
 2012 Saudi Ophthalmological Society, King Saud University. All rights reserved.
doi:10.1016/j.sjopt.2012.02.010Introduction
Uveal melanoma is the most common intraocular tumor in
adults,1 arising in either the ciliary body, iris, or choroid.2 The
neoplasm is most commonly manifested in the choroid (80%
of all uveal melanoma) followed by the ciliary body (10%)3
and iris (10%).4 Although rare in adults, the malignancy is
deadly when metastasized in the liver.5Clinical features
Patients often feel no symptom; however, depending on
the size and location of the tumor, they may present blurred
vision, visual field defects, flashes, floaters, or pain.1 Fundus
photography allows a visual classification depending on the
degree of pigmentation and the shape of the lesion (nodular,
flat, dome-shaped, mushroom shaped, or diffuse) (Fig. 1).4
Patients with choroidal masses undergo A-scan and B-scan
ultrasound examinations (Fig. 2). Choroidal melanoma
reveals a sharply rising and well-outlined surface signal withPeer review under responsibility
of Saudi Ophthalmological Society,
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movement of individual spikes in A-scan ultrasonography.
B-scan ultrasonography reveals an acoustically hollow mass
and choroidal excavation. For tumors of at least 3 mm thick-
ness, the combination of A-scan and B-scan ultrasonography
is a diagnostic tool with greater than 95% accuracy.6
Differential diagnosis
Clinically, very small tumors are frequently indistinguish-
able to large nevi.2 Medium and large sized tumors are
efficiently identified with modern imaging techniques,
therefore only 1% of cases are misinterpreted by experi-
enced oncologists.2 Possible differential diagnoses include
choroidal nevi, disciform degeneration, peripheral disciform
degeneration, congenital hypertrophy of the retinal pig-
ment epithelium, and choroidal hemangioma, hemorrhagic
detachment of retinal pigment epithelium, melanocytoma,
choroidal detachment, uveal effusion, posterior scleritis,
metastatic carcinoma, choroidal osteoma, and chorioretinal
granuloma.7j Production and hosting by ElsevierAccess this article online: www.saudiophthaljournal.comwww.sciencedirect.com
h 2012.
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Figure 1. Dome-shaped choroidal melanoma: (A) fundus photography
and (B) gross examination.
Figure 2. Ultrasound of a choroidal melanoma: (I) B-scan and (II) A-scan.
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Uveal melanoma comprises two prominent cell types: epi-
thelioid and spindle (Fig. 3). Epithelioid cells have abundant
glassy cytoplasm, a well-defined border, and abundantFigure 3. Histopathology of uveal melanoma: (A) spindle cells and (B)
epithelioid cells.extracellular space between cells. Nucleoli are very large
and eosinophilic within the center of the nucleus. Spindle cells
are smaller, less pleomorphic, with smaller nuclei, and stacked
tightly with little extracellular space. Based on their nucleus,
spindle cells can be sub-categorized. Subtype A has a narrow
nucleus with fine chromatin and indistinguishable nucleolus. A
common feature is a longitudinal fold in the nuclear envelope
resembling a chromatin streak. Subtype B has a rounder nu-
cleus, thicker chromatin, and more prominent nucleoli.
Callender and colleagues8 proposed a classification
scheme based on the aforementioned histopathological fea-
tures. Additionally, features such as fascicular patterns and
extensive necrosis determine tumor category. The most com-
mon forms of uveal melanoma are mixed epithelioid-spindle
cell tumors, representing 48% of all cases, and spindle-B cell
tumors (32%). Less common are the necrotic (8%), spindle-A
(6%), fascicular (5%), and epithelioid (2%) forms of the tumor.9
A simplified version of Callender’s classification was pro-
posed by the Armed Forces Institute of Pathology.2,10,11
Uveal melanoma is categorized as either spindle cell or mixed




Of all cellular features, nucleoli size prevails as the best
predictor of patient outcome. Although time consuming,
measuring the standard deviation of nucleoli area, circumfer-
ence, length, and width is reproducible, objective, and
strongly correlated with patient prognosis.12–14
Tumor size
The dimension of uveal melanoma has been proven to be
relevant to patient prognosis; however, many challenges
come when measuring the size of an irregularly shaped
mass.2 The most important factor to be considered is the
largest measurable tumor dimension.15–17
Mitotic activity
Mitotic figures are a strong prognostic factor, though they
are scarce in uveal melanomas. A minimum of 40 high power
fields at 40 magnification should be evaluated for mito-
sis.15–18
Tumor-infiltrating lymphocytes
Although lymphocytes are a mechanism of defense
against cancer, their infiltration into the tumor is an indication
of poor prognosis.16,17,19 T-cells are more commonly seen in
uveal melanoma; however, both T- and B-lymphocytes corre-
late with higher mortality rates.16
Tumor-infiltrating macrophage
Macrophages can be stained using the monoclonal anti-
body PG-M1, which binds to the CD68 epitope. Infiltrating
macrophages can be found in 83% of uveal melanoma
cases20 and is a valid prognostic factor.
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Neovascularization is a natural response to uveal mela-
noma; however, it unfortunately contributes to circulating
metastasis.17,21,22 The vessels may be arranged in a number
of patterns,17 but the strongest prognostic factor lies in the
presence of loop-like patterns. Classification may be
achieved through three groups: the presence of loops, pres-
ence of equivocal loops, and the absence of loops. The first
group is indicative of poorer prognosis.23Age
The survival rates of patients decrease with age.14,17 It is
theorized that older patients have a higher risk of metastatic
uveal melanoma, explaining the difference in survival rates.2Circulating malignant cells
Circulating malignant cells (CMCs) can be detected
regardless of the stage of disease.24,25 They may colonize
other organs, go into a dormancy phase, and occasionally
seed new CMCs into the bloodstream.26 Their value as a
prognostic factor is still a matter of debate.27Metastasis
Even though there were advances in the diagnosis and
treatment of the primary tumor, the 5 year mortality rate of
uveal melanoma patients remains almost unchanged since
1973.28 The survival rates at 5, 10, and 15 years are 65%,
52%, and 46%, respectively.29,30 Metastasis occurs mainly in
the liver, which is involved in 71.4–87% of patients with met-
astatic disease.31–33 The liver is the exclusive site of systemic
metastasis in 40% of the patients and is often the first meta-
static site in patients.34 Unfortunately, when liver metastases
are detected, treatment options are limited and life expec-
tancy is poor, with median survival time ranging between
2.2 and 12.5 months, probably reflecting technological ad-
vances that diagnosis metastasis earlier.33,35
The eye does not have lymphatics and the dissemination
of the primary tumor occurs through a hematogenous
way.36 Although the liver is the main site of metastasis, the
cells that escape the primary tumor first encounter the capil-
lary beds of the lungs. The reason why the liver is the main
site of uveal melanoma metastasis remains unclear. It might
be a mixture of two factors: reflection of homing of tumor
cells to this organ or simply preferential growth and survival
of these uveal melanoma cells in this microenvironment.
Uveal melanoma cells have the capacity to line, or even
create vascular-like channels.37Gene expression
Recent studies about the metastatic process of uveal mel-
anoma cells allowed the discovery of alterations associated
with low or high risk of metastatic death.38 Down-regulation
of melanoma-specific genes including the helix–loop–helix
inhibitor ID2 was found in tumors associated with a high risk
of metastatic death along with a corresponding increase in E-
cadherin expression,39 as well as colocalization of E-cadherinand h-catenin to the plasma membrane, which possibly impli-
cates a Wnt signaling pathway.
Other factors associated with metastasis are the up-regu-
lation of insulin receptor substrate-2, fibronectin 1, and cyto-
keratin 1840 and the decrease in vimentin and melanoma-
specific markers, such as MelanA and CD63.40
Increased levels of c-Met expression in the primary tumors
of patients significantly elevated the risk of those patients to
develop subsequent liver metastasis.41HGF and c-Met
The hepatocyte growth factor (HGF), also known as scatter
factor, and its corresponding receptor c-Met, play a role in
specific growth of cells in the liver. After activation by HGF,
c-Met is autophosphorylated on two tyrosine residues. This
initiates the formation of a docking site that can recruit intra-
cellular adapter proteins, such as growth factor receptor
bound protein 2, phosphatidylinositol 3-kinase, Shc, and
Src,42 which leads to multiple downstream signaling path-
ways, including the Ras protein kinase pathway. These path-
ways give rise to the up-regulation of multiple genes and can
increase cellular proliferation, cell cycle progression, protec-
tion from apoptosis, increased cellular motility, and invasive
ability.42IGF-I and IGF-IR
Activation of IGF-IR has been shown to play a role in
essential steps of the metastasis process: cellular prolifera-
tion, protection from apoptosis, migration, integrin-medi-
ated adhesion to the extracellular matrix, and invasion of
basement membranes.43 Targeting of this pathway by using
a specific inhibitor of IGF-IR tyrosine phosphorylation called
cyclolignan picropodophyllin was shown to cause tumor
regression in a xenograft mouse model.44
Phosphorylated Akt has also relates with increased metas-
tasis in patients with uveal melanoma. It is possible that this
elevated mortality rate may reflect the activation of Akt
through the IGF-I pathway.45CXCR4 and CXCL12 (chemokines)
Tumors can express CXCR4, and this expression correlates
with markers of poor prognosis.46,47 Activation of CXCR4 by
CXCL1 (stromal derived factor-1), a chemokine, has been
shown to lead to a variety of intracellular signal transduction
pathways and regulation of cellular survival, proliferation,
migration, and adhesion.48 Among the multiple pathways
that are activated is phosphatidylinositol 3-kinase, which
subsequently phosphorylates Akt. As mentioned previously,
activated Akt is associated with worse prognosis in uveal
melanoma and plays a role in proliferation of cells as well
as migration.49
Recently, it has been shown that cancer cells are capable
of exploiting and hijacking this system to facilitate their
movement and extravasation out of the primary site and into
systemic circulation.50 It has also been hypothesized and
widely believed that the CXCR4/CXCL12 mono-axis may play
a critical role in guiding circulating malignant cells (CXCR4-
positive cells) to organ-specific locations that actively secrete
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the liver.51Conclusion
Despite the advances on diagnosis and treatment of the
uveal melanoma, the survival of the patients has not im-
proved yet. Nevertheless, the recent discoveries about the
metastasis process in this disease, such as the up and down-
regulation of some genes seems to be promising therapeutic
targets to change the prognosis of this neoplasia.References
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